Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).

Chun Loo Gan,Shaan Dudani,Connor Wells,Frede Donskov,Sumanta K. Pal,Nazli Dizman,Nityam Rathi,Benoit Beuselinck,Flora Yan,Aly-Khan A. Lalani,Aaron Richard Hansen,Bernadett Szabados,Guillermo Velasco,Ben Tran,Jae Lyun Lee,Ulka N. Vaishampayan,Georg A. Bjarnason,Mathushan Subasri,Toni K. Choueiri,Daniel Yick Chin Heng

Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).

2020

639Background: Cabozantinib (Cabo) is approved for mRCC patients based on the METEOR and CABOSUN trials. The real-world effectiveness of Cabo in mRCC patients in the first- (1L), second- (2L), thir...

Keywords:

Pathology
Oncology
Renal cell carcinoma
Cabozantinib
Internal medicine
Medicine

Correction
Source
Cite
Save

References

Citations